{
    "clinical_study": {
        "@rank": "109383", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Experimental", 
                "description": "The weekly treatment of the 6 mg HM11260C or placebo will be maintained"
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Experimental", 
                "description": "The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Experimental", 
                "description": "The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label\n      Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator\n      on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus"
        }, 
        "brief_title": "A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objective\n\n      - effect of multiple different weekly and monthly doses of HM11260C and liraglutide\n      (Victoza) as active control on gastric emptying\n\n      Secondary Objectives\n\n        -  evaluate the pharmacodynamic (PD) effects of multiple weekly and monthly doses of\n           HM11260C and liraglutide after a Mixed Meal Tolerance Test\n\n        -  evaluate the islet \u03b2-cell function after a graded glucose infusion (GGI) of different\n           doses of HM11260C and liraglutide\n\n        -  evaluate safety and tolerability of different doses of HM11260C and liraglutide\n\n        -  evaluate the pharmacokinetic (PK) effect of multiple weekly and monthly doses of\n           HM11260C"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u226518 to \u2264 70 years of age at the time of the Screening Visit\n\n          -  History of type 2 diabetes\n\n          -  Body mass index (BMI) \u226518 to \u226445 kg/m2 at the Screening Visit\n\n          -  Use of approved methods of contraception\n\n          -  Ability to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Significant acute diabetic proliferative retinopathy or severe neuropathy\n\n          -  Systolic blood pressure >160 mm Hg and/or diastolic blood pressure >100 mm Hg at\n             screening\n\n          -  Pregnant or lactating women\n\n          -  Participation in an investigational study within 30 days prior to randomization\n\n          -  History of any major surgery within 6 months prior to Screening\n\n          -  History of any serious adverse reaction or hypersensitivity to any of the product\n             components.\n\n          -  History of renal disease or significantly abnormal kidney function tests at Screening\n\n          -  History of hepatic disease or significantly abnormal liver function tests\n\n          -  History of any active infection within 30 days prior to Randomization\n\n          -  Presence of clinically significant physical, laboratory, or ECG findings at Screening\n             that, in the opinion of the Investigator, may interfere with any aspect of study\n             conduct or interpretation of results\n\n          -  Concurrent conditions that could interfere with safety and/or tolerability\n             measurements per the investigator\n\n          -  Donation or loss of >500 mL of blood or blood product within 56 days of Randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059564", 
            "org_study_id": "HM-EXC-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B"
                ], 
                "description": "doses of 6 mg, 16 mg", 
                "intervention_name": "HM11260C", 
                "intervention_type": "Drug", 
                "other_name": "LAPS-Exendin-4"
            }, 
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B"
                ], 
                "description": "Normal saline solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline solution"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "description": "doses of 1.8 mg", 
                "intervention_name": "Victoza", 
                "intervention_type": "Drug", 
                "other_name": "Liraglutide"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes Mellitus", 
            "Diabetes Mellitus, Type 2", 
            "Glucose Metabolism Disorders", 
            "Metabolic Diseases", 
            "Endocrine System Diseases", 
            "Exendin-4"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "contact": {
                "email": "clinical4@hanmi.co.kr", 
                "last_name": "Hanmi Clinical"
            }, 
            "facility": {
                "address": {
                    "city": "California", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Hanmi"
            }, 
            "investigator": {
                "last_name": "Hanmi Clinical", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "clinical4@hanmi.co.kr", 
            "last_name": "Hanmi Clinical"
        }, 
        "overall_official": {
            "affiliation": "California, United States", 
            "last_name": "Hanmi Clinical", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cmax, AUC at 13 weeks", 
            "measure": "PK profile of acetaminophen", 
            "safety_issue": "No", 
            "time_frame": "13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Fasting plasma glucose (FPG), Postprandial glucose (PPG), Insulin, C-peptide, HbA1c at 13 weeks", 
                "measure": "Glucose metabolism", 
                "safety_issue": "No", 
                "time_frame": "13 weeks"
            }, 
            {
                "description": "Incidence and severity of adverse events, findings on physical examination, clinical laboratory abnormalities at 18 weeks", 
                "measure": "Safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}